Search | Médecins Sans Frontières Access Campaign

About us
About the Access Campaign

Some of our 2023 plans

Media room

Latest news

Jobs
Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.
Our work
COVID-19

Explainer: A bold proposal at the WTO by India and South Africa

Diabetes

Drug-resistant infections

HIV/AIDS

Hepatitis C

Hypertension

Patents and intellectual property

Pandemic prevention, preparedness and response

The Patent Oppositions Database

Research and development

Spotlight on: the Big Pharma double-dip

Transparency Matters: Clinical Trials Costs

Tropical and neglected diseases

Spotlight on: Snakebite

Tuberculosis

Vaccines

Explainer: COVID-19 vaccines - Recommendations for equitable access
Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.
Get involved
Campaign success stories

#NoMoreTears Johnson & Johnson Can you hear us?

A Fair Shot

Novartis 'Drop the case'

Trans-pacific Partnership (TPP)

Recent campaigns

Time for $5

No Patents in a Pandemic

Share the Tech - Save Lives
Take Action

Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.
Resources
Press releases

Statements

Letters

Opinion articles

Feature stories

Interviews

Blog

Newsletters

Publications

Research articles

Topic overview pages

Spotlight pages

Videos

Photo stories

Infographics

Events
Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.

Medicines shouldn’t be a luxury Take action

17 results found

A Nurse examines medications in the storeroom at the TB Practecal Warehouse in Nukus, Uzbekistan.

Press release |

03 May 2022

MSF responds to new WHO guidance recommending vastly shorter, improved and better-tolerated treatment for multidrug-resistant TB

The World Health Organization (WHO) announced global treatment guidance with new, safer and more effective six-month oral treatment regimen for multidrug-resistant tuberculosis.

Tags Tuberculosis tuberculosis pretomanidlinezolidbedaquiline World Health Organization

MSF Counsellor, counselling parents of a six-year-old girl with drug-resistant TB at MSF independent Clinic, Mumbai- India

Press release |

03 September 2021

Lifesaving TB medicines must be affordable and available to make all-oral treatments for children a reality

The WHO recently released new rapid guidance recommending that children of all ages with drug-resistant tuberculosis (DR-TB) have access to all-oral treatment using the drugs bedaquiline and/or delamanid. However paediatric ...

Tags Tuberculosis tuberculosis bedaquilinedelamanid World Health OrganizationJohnson & Johnson

MSF and TB activists disrupt opening of TB conference to protest drug corporations keeping life-saving medicines from people

Press release |

30 October 2019

MSF and TB activists disrupt opening of TB conference to protest drug corporations keeping life-saving medicines from people

Newer medicines for DR-TB are desperately needed, but barriers to access, including high prices, keep them out of reach for most people around the world.

Tags Tuberculosis drug-resistant TBtuberculosis pretomanidbedaquilinedelamanid Union Conference on Lung HealthTB AllianceJohnson & Johnson

South Africa has one of the highest burdens of TB and (Drug Resistant) DR-TB in the world, with around 20,000 people diagnosed with DR-TB in 2015. In Khayelitsha, Western Cape, which has some of the country’s highest rates of DR-TB, MSF runs a strengthened regimen programme that incorporates new drugs into treatment regimens for DR-TB patients including Delamanid and Bedaquiline.

Feature story |

28 September 2018

The Story of Goodman Mkhanda

Tags Tuberculosis drug-resistant TBtuberculosis delamanid access to medicines South Africa

Yury, pictured above, is the first patient has successfully finished their TB treatment at MSF’s project in the Republic of Belarus in Eastern Europe.

Feature story |

01 September 2017

Belarus: "My doctors told me – 'this is the only chance’"

Tags Tuberculosis drug-resistant TBtuberculosis bedaquilinedelamanid Belarus

Report Cover Out of Step 2017 - 3rd edition

Report |

05 July 2017

Out of Step: TB policies in 29 countries, 3rd Ed.

Out of Step 2017 includes the results of a 29-country survey on national TB policies and practices. The report was created to identify gaps in implementation and monitor progress towards ending TB.

Tags Tuberculosis drug-resistant TBtuberculosis bedaquilinedelamanid Stop TB Partnership [TB] Out of Step #StepUpforTB

Gift mugs offered during the "accomplished MDR-TB treatment" graduation in the MSF Matsapha clinic. Matsapha, Manzini Region, Swaziland. Photograph by Alexis Huguet

Feature story |

15 June 2017

‘A long and gruelling seven years and now it is over’

Tags Tuberculosis drug-resistant TBtuberculosis bedaquilinedelamanid access to medicines Eswatini

Sinethemba takes her daily regimen for XDR-TB at 10am each day. She also takes two additional delamanid tablets at night. She is 16 years old, lives with her grandmother, Vuyisiwa Madubela, and four other family members in a two-bedroomed home in Zone C29, Khayelitsha, Western Cape, South Africa. Her grandmother’s determination and love, combined with receiving a six-month trial of one the newest DR-TB drugs on the market likely saved her life this year.

Press release |

23 March 2017

Fewer than 5% of people in need are treated with new TB drugs, nearly four years after their approval

Tags Tuberculosis drug-resistant TBtuberculosis bedaquilinedelamanid Johnson & JohnsonOtsuka

Goderdzi Rajabishvili, an ambulatory patient at the National Centre for Tuberculosis and Lung Disease in Georgia’s capital, Tbilisi, receives his twice-daily infusion of imipenem, an antibiotic used to treat MDR-TB.

Press release |

06 March 2017

endTB partnership launches clinical trial to target toughest strains of tuberculosis

Tags Tuberculosis drug-resistant TBtuberculosis bedaquilinedelamanid Georgia

Pooja Iyer, MSF counselor, providing counseling to Hanif, an XDR-TB patient, in the MSF clinic in Mumbai. India 2016

Press release |

30 January 2017

Health groups call on Government of India to urgently make lifesaving TB drug available

Tags Tuberculosis drug-resistant TBtuberculosis bedaquilinedelamanid Otsuka India

Letter |

21 January 2017

Health groups letter to Indian Government to make Delamanid available

Tags Tuberculosis tuberculosis delamanid India

In Tajikistan, in an attempt to breakup the everyday routine for children undergoing TB treatment, MSF’s psychosocial team organises celebration parties as part of MSF’s pediatric therapeutic play programme.

Feature story |

07 November 2016

TB Patients in Tajikistan Celebrate New Treatment Access

Tags Tuberculosis drug-resistant TBtuberculosis bedaquilinedelamanid Tajikistan

Simphiwe holds his first delamanid tablets, which have now been included into his treatment regimen for XDR-TB, October 2016.

Press release |

26 October 2016

MSF reports on use of the new TB drugs bedaquiline and delamanid

Tags Tuberculosis drug-resistant TBtuberculosis bedaquilinedelamanid Union Conference on Lung HealthWorld Health Organization

MSF149387

Press release |

21 March 2016

Just 2% of people with the severest cases of drug-resistant TB currently have access to new, more effective treatments

Tags Tuberculosis tuberculosisdrug-resistant TB bedaquilinedelamanid World TB DayJohnson & JohnsonOtsuka

TB-cabinets are important for an effective walk-in treatment. Here ambulatory treatment, psychosocial counselling for patients and their families, and social packages (nutritional support, hygiene kits and transport money) are provided to help patients adhere to treatment.

Press release |

24 February 2016

Developing countries hit with high price for important new tuberculosis drug

Developing countries hit with high price for important new tuberculosis drug

Tags Tuberculosis drug-resistant TBtuberculosis delamanid Otsuka

An Extensively Drug Resistant Tuberculosis (XDR-TB) patient undergoing an audiometry test to assess the hearing ability, as hearing loss is one of the side-effects of DRTB drugs

Press release |

29 April 2015

MSF response to announcement of Otsuka’s donation programme for the TB drug delamanid

Tags Tuberculosis drug-resistant TBtuberculosis delamanid access to medicines Otsuka

Press release |

01 July 2014

More MSF patients with DR-TB gain access to dramatically cheaper version of life-saving drug

Tags Tuberculosis drug-resistant TBtuberculosis linezolid South Africa